If roflumilast inhibits the innate immunity in the stable patient, what about infection?
- 23 March 2012
- journal article
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 7 (1) , e11-e12
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Roflumilast inhibits the release of chemokines and TNF‐α from human lung macrophages stimulated with lipopolysaccharideBritish Journal of Pharmacology, 2011
- Anti-Tissue Antibodies Are Related to Lung Function in Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Antinuclear autoantibodies are more prevalent in COPD in association with low body mass index but not with smoking historyThorax, 2010
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderlyRheumatology, 2010
- Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- In vitrodifferentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor‐αrelease by PDE inhibitorsBritish Journal of Pharmacology, 1997